No quarterly revenue total was found in REPLIMUNE GROUP, INC.'s SEC filings.
Replimune Group, Inc. (REPL) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$47.8 million. As of Sep 30, 2026 it held $307.8 million in cash and investments and $127.2 million in total debt.
Revenue
—
Net income
$-57.12M
+31.3% vs year-ago quarter
Operating cash flow
$-47.70M
+41.3% vs year-ago quarter
Free cash flow
$-47.78M
+42.1% vs year-ago quarter
EPS
$-0.54
+40.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
94.80M
+20.9% vs year-ago quarter
Net cash
$180.64M
Q2 FY2027
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- REPL (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Woburn, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1737953
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2027 Sep 30, 2026 |
Q1 FY2027 Jun 30, 2026 |
Q4 FY2026 Mar 31, 2026 |
Q3 FY2026 Dec 31, 2025 |
Q2 FY2026 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$56.3M | -$68.2M | -$73.3M | -$71.9M | -$84.3M |
| Net income | -$57.1M | -$69.8M | -$73.2M | -$70.9M | -$83.1M |
| Diluted EPS | -$0.54 | -$0.72 | -$0.77 | -$0.77 | -$0.90 |
| Operating cash flow | -$47.7M | -$75.7M | -$56.2M | -$66.0M | -$81.2M |
| Free cash flow | -$47.8M | -$75.7M | -$56.2M | -$66.1M | -$82.6M |
| Total assets | $373.9M | $252.4M | $332.4M | $333.6M | $389.4M |
| Total liabilities | $169.2M | $146.8M | $166.2M | $123.1M | $126.1M |
| Stockholders' equity | $204.8M | $105.6M | $166.2M | $210.5M | $263.3M |
| Cash and investments | $307.8M | $195.3M | $268.9M | $269.1M | $323.6M |
| Total debt | $127.2M | $112.0M | $111.6M | $76.3M | $76.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Sep 16, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K/A |
Amended current report
Other events
|
Aug 11, 2026 | Aug 9, 2026 |
All 657 Replimune Group, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.